LKB1 Loss Is Associated with Resistance to Anti-Angiogenic Therapy in Non-Small Cell Lung Cancer Mouse Models

被引：0
|
作者：
Guijarro, I. [1 ]
Poteete, A. [1 ]
Fan, Y. [1 ]
Cho, S. [1 ]
Tong, P. [1 ]
Roarty, E. [1 ]
Nilsson, M. [1 ]
Rodriguez-Canales, J. [2 ]
Mino, B. [2 ]
Cuentas, E. Parra [2 ]
Wistuba, I. [2 ]
Wang, J. [3 ]
Heymach, J. [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[2] MD Anderson, Translat Mol Pathol, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
LKB1; Anti-angiogenic therapy; Resistance;
D O I：
10.1016/j.jtho.2017.09.1654
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.03-027
引用
收藏
页码：S2283 / S2283
页数：1
相关论文
共 50 条
  • [1] LKB1 loss is associated with resistance to VEGF inhibitors in non-small cell lung cancer (NSCLC)
    Guijarro, Irene
    Poteete, Alissa
    Yang, Chao
    Roarty, Emily
    Nilsson, Monique
    Sun, Huiying
    Tong, Pan
    Chang, Edward
    Rodriguez-Canales, Jaime
    Mino, Barbara
    Parra, Edwin
    Wistuba, Ignacio
    Wang, Jing
    Heffernan, Timothy
    Heymach, John V.
    CANCER RESEARCH, 2016, 76
  • [2] Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer
    Tian, Wentao
    Cao, Chenghui
    Shu, Long
    Wu, Fang
    ONCOTARGETS AND THERAPY, 2020, 13 : 12113 - 12129
  • [3] LOSS OF LKB1 IS ASSOCIATED WITH RESISTANCE TO IFN-GAMMA AND T CELL KILLING IN NON-SMALL CELL LUNG CANCER
    Reuben, Alexandre
    Jiang, Peixin
    Nie, Hui
    Cobo, Ana Galan
    Dang, Minghao
    Qian, Yu
    Frank, Meredith
    Blitz, Emily
    Hamdi, Haifa
    Denning, Warren
    Nilsson, Monique
    Poteete, Alissa
    Shen, Li
    Wang, Qi
    Guijarro, Irene
    Nichols, Keri
    Khairullah, Roohussaba
    Zhang, Jiexin
    Skoulidis, Ferdinandos
    Wang, Jing
    Wang, Linghua
    Heymach, John
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A960 - A960
  • [4] Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
    Tan, Aaron C.
    Pavlakis, Nick
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (16)
  • [5] Advances in Predictive Biomarkers for Anti-Angiogenic Therapy in Non-Small Cell Lung Cancer
    Zhao, Weixing
    Jiang, Jun
    CANCER CONTROL, 2024, 31
  • [6] Anti-angiogenic agents in the treatment of non-small cell lung cancer
    Szyszka-Barth, Katarzyna
    Ramlau, Katarzyna
    Stencel, Dariusz
    Ramlau, Rodryg
    KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2014, 11 (02) : 145 - 150
  • [7] LKB1 loss sensitizes non-small cell lung cancer cells to aggravation of ER stress
    Inge, Landon J.
    Friel, Jacqueline M.
    Fowler, Aaron
    Richer, Amanda
    Whitsett, Timothy
    Tran, Nhan L.
    Bremner, Ross M.
    CANCER RESEARCH, 2014, 74 (19)
  • [8] Acquired Resistance to Anti-VEGF Therapy in Non-Small Cell Lung Cancer Is Not Associated with Angiogenic Compensation
    Frink, Robin E.
    Sullivan, Laura A.
    Du, Wenting
    Barraza, Ashley
    Brekken, Rolf A.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S608 - S608
  • [9] Beyond Conventional: The New Horizon of Anti-Angiogenic microRNAs in Non-Small Cell Lung Cancer Therapy
    Tirpe, Alexandru
    Gulei, Diana
    Tirpe, George Razvan
    Nutu, Andreea
    Irimie, Alexandru
    Campomenosi, Paola
    Pop, Laura Ancuta
    Berindan-Neagoe, Ioana
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (21) : 1 - 22
  • [10] Mutations of the LKB1/STK11 gene in non-small cell lung cancer with loss of heterozygosity
    Yang, Sei-Hoon
    Meerzaman, Daoud
    Mechanic, Leah E.
    Gill, Rajbir
    Dracheva, Tatiana
    Han, Seung-Bum
    Kim, Sam-Yong
    Bowman, Elise D.
    Harris, Curtis C.
    Jen, Jin
    ANNALS OF ONCOLOGY, 2006, 17 : 246 - 246
12345